Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?

This study has been completed.
Sponsor:
Collaborators:
California Breast Cancer Research Program
The Wellness Community
The Dana Foundation
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186524
First received: September 14, 2005
Last updated: March 11, 2011
Last verified: March 2011
  Purpose

Women with primary breast cancer may benefit from participating in supports groups as they cope with treatment and the psychological challenges of survivorship. Studies have documented that these women benefit from support groups run in a university setting; however, no one has documented that they benefit from community cancer support groups. Many community cancer support groups exist and provide service to a large number of women with breast cancer. It is important to know if these groups are providing comparable service to well researched support groups. We conducted this study as the first randomized study of community compared to university-style support groups. Women had a 50/50 chance of being assigned to either a community or a university style support group based on a coin flip. This study took place in two sites The Wellness Community East Bay (Walnut Creek) and San Francisco. Two community groups were studied.

i) This study evaluated the strengths and weaknesses of two community-based support group interventions for breast cancer patients [The Wellness (TWC) and Cancer Support (CSC) Communities, in the San Francisco area]. We compared them with a type of therapy developed in the university setting (Stanford's Supportive-Expressive group therapy), studied which aspects are most effective, and who benefits the most. We compared these women on change in emotional distress, means of coping with cancer, and social and family support. In addition, change in physiological response to stress was measured using saliva samples.

ii) We were able to achieve recruitment for 6 of 8 groups proposed. We randomized 72 women in blocks of 12 taking consecutive women per site until we accrued 12 for each group. Of those, 61 women actually attended groups, of those 46 women to date completed at least one follow-up and were available for analysis for this report. We screened 108 women, 16 who were screened out on initial phone contact, 20 women began to go through our baseline interviews and assessments and either decided not to enroll or dropped out before we could compose a group for the second S.F. randomization. Our final two follow-up assessments for our final group in the East Bay are being conducted right now (8 month) and will be conducted in October, 2002 (12 month) so they are not available for assay or analysis for this final report.

iii) We examined 5 outcome variables for this report and found that women participating in the community groups changed at about the same level over the 4 months of group therapy as the women in the Stanford groups. This was true for depression symptoms, trauma symptoms, social support, self-efficacy, and post-traumatic-growth. These analyses are preliminary until we complete our final follow-up assessments. It is encouraging for the community groups that women benefited at the same rate as they did in the well-researched Stanford groups. Conclusions for this study are somewhat limited because we could not complete the recruitment of our entire sample. However, there is every reason to suppose that community groups are as effective at serving women with primary breast cancer as Stanford's groups though they are based on very different ideas of therapy. It is important to note that all of these groups were led by therapists, and that we may have found other results if the groups had been led by peers or other types of professionals. This study reduces the human and economic cost of breast cancer in California by validating community groups usually offered free to women with breast cancer.


Condition Intervention Phase
Breast Cancer
Behavioral: Breast Cancer Support Group
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Stanford University:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  1. be > 18 years old
  2. be diagnosed with primary breast cancer (Stages I-III, without metastasis or recurrence) within the past 5 years
  3. be able to read, speak, and understand English;
  4. be < 18 months post treatment; -

Exclusion Criteria:

participation in more than 8 sessions of a support group.

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186524

Locations
United States, California
Cancer Support Community
San Francisco, California, United States, 94115
Stanford University
Stanford, California, United States, 94305-5718
The Wellness Community
Walnut Creek, California, United States, 94597
Sponsors and Collaborators
Stanford University
California Breast Cancer Research Program
The Wellness Community
The Dana Foundation
Investigators
Principal Investigator: David Spiegel, M.D. Stanford University
Study Director: Janine Giese-Davis, Ph.D. Stanford University
Principal Investigator: Mitch Golant, Ph.D. The Wellness Community
Principal Investigator: Carol Kronenwetter, Ph.D. Cancer Support Community
  More Information

Publications:
Responsible Party: David Spiegel, MD, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00186524     History of Changes
Other Study ID Numbers: 4 BB-2901
Study First Received: September 14, 2005
Last Updated: March 11, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

ClinicalTrials.gov processed this record on October 23, 2014